Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31

Novartis's Pluvicto was approved by the Food and Drug Administration for use in combination with an androgen receptor pathway inhibitor. "Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto," at 5:06 p.m. ET on July 31, incorrectly said Pluvicto was approved for use in combination with an androgen receptor pathway inhibitor and androgen deprivation therapy.

(END) Dow Jones Newswires

August 03, 2026 17:52 ET (21:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may